NO861409L - Et plasminogenaktivatorinneholdende middel. - Google Patents
Et plasminogenaktivatorinneholdende middel.Info
- Publication number
- NO861409L NO861409L NO861409A NO861409A NO861409L NO 861409 L NO861409 L NO 861409L NO 861409 A NO861409 A NO 861409A NO 861409 A NO861409 A NO 861409A NO 861409 L NO861409 L NO 861409L
- Authority
- NO
- Norway
- Prior art keywords
- plasminogen activator
- saccharide
- acid ester
- medicine according
- optionally
- Prior art date
Links
- 102000013566 Plasminogen Human genes 0.000 title description 2
- 108010051456 Plasminogen Proteins 0.000 title description 2
- 102000001938 Plasminogen Activators Human genes 0.000 claims description 14
- 108010001014 Plasminogen Activators Proteins 0.000 claims description 14
- 229940127126 plasminogen activator Drugs 0.000 claims description 14
- 108090000373 Tissue Plasminogen Activator Proteins 0.000 claims description 13
- 102000003978 Tissue Plasminogen Activator Human genes 0.000 claims description 13
- 229960000187 tissue plasminogen activator Drugs 0.000 claims description 13
- 239000002253 acid Substances 0.000 claims description 11
- 150000002148 esters Chemical class 0.000 claims description 11
- 235000000346 sugar Nutrition 0.000 claims description 11
- 150000001720 carbohydrates Chemical class 0.000 claims description 10
- 229940079593 drug Drugs 0.000 claims description 10
- 239000003814 drug Substances 0.000 claims description 10
- 108010010803 Gelatin Proteins 0.000 claims description 4
- 229920000159 gelatin Polymers 0.000 claims description 4
- 235000019322 gelatine Nutrition 0.000 claims description 4
- 235000011852 gelatine desserts Nutrition 0.000 claims description 4
- 239000003381 stabilizer Substances 0.000 claims description 4
- HTTJABKRGRZYRN-UHFFFAOYSA-N Heparin Chemical compound OC1C(NC(=O)C)C(O)OC(COS(O)(=O)=O)C1OC1C(OS(O)(=O)=O)C(O)C(OC2C(C(OS(O)(=O)=O)C(OC3C(C(O)C(O)C(O3)C(O)=O)OS(O)(=O)=O)C(CO)O2)NS(O)(=O)=O)C(C(O)=O)O1 HTTJABKRGRZYRN-UHFFFAOYSA-N 0.000 claims description 3
- 229920000669 heparin Polymers 0.000 claims description 3
- 229960002897 heparin Drugs 0.000 claims description 3
- 229940126601 medicinal product Drugs 0.000 claims description 3
- 238000000034 method Methods 0.000 claims description 3
- 102000009027 Albumins Human genes 0.000 claims description 2
- 108010088751 Albumins Proteins 0.000 claims description 2
- 102000008186 Collagen Human genes 0.000 claims description 2
- 108010035532 Collagen Proteins 0.000 claims description 2
- 229920001436 collagen Polymers 0.000 claims description 2
- 239000008273 gelatin Substances 0.000 claims description 2
- 239000000203 mixture Substances 0.000 claims description 2
- 108050006955 Tissue-type plasminogen activator Proteins 0.000 claims 2
- 208000005189 Embolism Diseases 0.000 claims 1
- 101000801481 Homo sapiens Tissue-type plasminogen activator Proteins 0.000 claims 1
- 208000007536 Thrombosis Diseases 0.000 claims 1
- 102000047823 human PLAT Human genes 0.000 claims 1
- 150000008163 sugars Chemical class 0.000 description 2
- 206010014523 Embolism and thrombosis Diseases 0.000 description 1
- 102000009123 Fibrin Human genes 0.000 description 1
- 108010073385 Fibrin Proteins 0.000 description 1
- BWGVNKXGVNDBDI-UHFFFAOYSA-N Fibrin monomer Chemical compound CNC(=O)CNC(=O)CN BWGVNKXGVNDBDI-UHFFFAOYSA-N 0.000 description 1
- 229920002971 Heparan sulfate Polymers 0.000 description 1
- 108010023197 Streptokinase Proteins 0.000 description 1
- QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 1
- 108090000435 Urokinase-type plasminogen activator Proteins 0.000 description 1
- 102000003990 Urokinase-type plasminogen activator Human genes 0.000 description 1
- 239000012190 activator Substances 0.000 description 1
- 239000003054 catalyst Substances 0.000 description 1
- 230000009089 cytolysis Effects 0.000 description 1
- 229960000633 dextran sulfate Drugs 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 229950003499 fibrin Drugs 0.000 description 1
- 230000003480 fibrinolytic effect Effects 0.000 description 1
- 238000000760 immunoelectrophoresis Methods 0.000 description 1
- 229940012957 plasmin Drugs 0.000 description 1
- 229960005202 streptokinase Drugs 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 229960005356 urokinase Drugs 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/43—Enzymes; Proenzymes; Derivatives thereof
- A61K38/46—Hydrolases (3)
- A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
- A61K38/49—Urokinase; Tissue plasminogen activator
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Medicinal Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Immunology (AREA)
- Biomedical Technology (AREA)
- Pharmacology & Pharmacy (AREA)
- Gastroenterology & Hepatology (AREA)
- Epidemiology (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| DE19853512908 DE3512908A1 (de) | 1985-04-11 | 1985-04-11 | Gewebe-plasminogenaktivator (t-pa) enthaltendes mittel |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| NO861409L true NO861409L (no) | 1986-10-13 |
Family
ID=6267672
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| NO861409A NO861409L (no) | 1985-04-11 | 1986-04-10 | Et plasminogenaktivatorinneholdende middel. |
Country Status (8)
| Country | Link |
|---|---|
| EP (1) | EP0198321A1 (da) |
| JP (1) | JPS61236730A (da) |
| AU (1) | AU5595486A (da) |
| DE (1) | DE3512908A1 (da) |
| DK (1) | DK162086A (da) |
| ES (1) | ES8800599A1 (da) |
| IL (1) | IL78450A0 (da) |
| NO (1) | NO861409L (da) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2520975B2 (ja) * | 1989-09-21 | 1996-07-31 | 三井東圧化学株式会社 | 組織プラスミノ―ゲンアクチベ―タ―若しくはその誘導体を含有する血栓溶解剤 |
| JPH0791318B2 (ja) * | 1989-09-21 | 1995-10-04 | 三井東圧化学株式会社 | 蛋白質水溶液、蛋白質水溶液の濃度増大方法および蛋白質製剤 |
| WO2005011739A1 (en) * | 2003-08-05 | 2005-02-10 | Fuji Photo Film B.V. | Use of recombinant or synthetic gelatin as a stabiliser in vaccines |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR2310133A2 (fr) * | 1975-05-05 | 1976-12-03 | Fabre Sa Pierre | Nouveau medicament comportant un activateur du plasminogene perfectionne |
| CH630661A5 (en) * | 1978-01-01 | 1982-06-30 | Fabre Sa Pierre | Process for the production of a medicinal composition containing a plasminogen activator and a sulphated polysaccharide |
| FR2483234A2 (fr) * | 1980-05-29 | 1981-12-04 | Fabre Sa Pierre | Composition ophtalmique contenant un activateur du plasminogene |
-
1985
- 1985-04-11 DE DE19853512908 patent/DE3512908A1/de not_active Withdrawn
-
1986
- 1986-04-02 EP EP86104475A patent/EP0198321A1/de not_active Withdrawn
- 1986-04-08 IL IL78450A patent/IL78450A0/xx unknown
- 1986-04-09 ES ES553802A patent/ES8800599A1/es not_active Expired
- 1986-04-10 NO NO861409A patent/NO861409L/no unknown
- 1986-04-10 DK DK162086A patent/DK162086A/da not_active IP Right Cessation
- 1986-04-10 AU AU55954/86A patent/AU5595486A/en not_active Abandoned
- 1986-04-10 JP JP61081248A patent/JPS61236730A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| DK162086A (da) | 1986-10-12 |
| JPS61236730A (ja) | 1986-10-22 |
| AU5595486A (en) | 1986-11-06 |
| DE3512908A1 (de) | 1986-10-23 |
| ES8800599A1 (es) | 1987-11-16 |
| ES553802A0 (es) | 1987-11-16 |
| IL78450A0 (en) | 1986-08-31 |
| DK162086D0 (da) | 1986-04-10 |
| EP0198321A1 (de) | 1986-10-22 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Cercek et al. | Enhancement of thrombolysis with tissue-type plasminogen activator by pretreatment with heparin. | |
| US5084273A (en) | Composition of anticoagulants | |
| Magnani | Plasminogen Activator Italian Multicenter Study (PAIMS): comparison of intravenous recombinant single-chain human tissue-type plasminogen activator (rt-PA) with intravenous streptokinase in acute myocardial infarction | |
| EP0382174B1 (de) | Gewebs-Plasminogenaktivator-Derivat | |
| DE3689943T2 (de) | Degradierte Spezies eines Gewebeplasminogenaktivators, pharmazeutische Zubereitung und Verfahren zur Herstellung derselben. | |
| CA2129660A1 (en) | Tissue plasminogen activator glycosylation variants with improved therapeutic properties | |
| AU2036188A (en) | New tissue plasminogen activator | |
| DE4411143C2 (de) | Thrombosemittel | |
| NZ228401A (en) | Human tissue plasminogen activator (ht-pa) variants and processes for their production | |
| Novokhatny et al. | Thrombolytic potency of acid-stabilized plasmin: superiority over tissue-type plasminogen activator in an in vitro model of catheter-assisted thrombolysis | |
| Pollak et al. | Ancrod causes rapid thrombolysis in patients with acute stroke | |
| Cole et al. | Ancrod: a practical alternative to heparin | |
| AU3744889A (en) | Variants of plasminogen activators and processes for their production | |
| DE3804600A1 (de) | Mischung aus einer thrombolytisch wirkenden und einer antithrombotischen substanz | |
| NO861409L (no) | Et plasminogenaktivatorinneholdende middel. | |
| Flameng et al. | Coronary thrombolysis by intravenous infusion of recombinant single chain urokinase-type plasminogen activator or recombinant urokinase in baboons: effect on regional blood flow, infarct size and hemostasis | |
| EP0098814B1 (en) | Antithrombin-heparin complex | |
| US6759042B2 (en) | Use of cross-linked, covalently bound urokinase plasminogen activator (scuPA)-urokinase plasminogen activator receptor (suPAR) complex as a fibrinolytic agent | |
| Grossbard | Recombinant tissue plasminogen activator: a brief review | |
| Tranchesi Jr et al. | Effect of combined administration of saruplase and single-chain alteplase on coronary recanalization in acute myocardial infarction | |
| US5342616A (en) | Method of administering tissue plasminogen activator | |
| CA1303987C (en) | Pharmaceutical composition having thrombolytic activity | |
| Gaffhey | Tissue plasminogen activator for thrombolytic therapy: expectation versus reality | |
| US5174994A (en) | Pharmaceutical composition having thrombolytic activity | |
| EP0226172B1 (de) | Mittel aus einem Plasmin-Inhibitor und einem Plasminogen-Aktivator zur Behandlung von Thrombosen |